OpenLB
Open Library of Bioscience
Advanced Search
Human vaccines & immunotherapeutics
10 03, 2021;17 (10): 3276-3280.

Landscape and progress of global COVID-19 vaccine development.

Hui-Yao Huang, Shu-Hang Wang, Yu Tang, Wei Sheng, Chi-Jian Zuo, Da-Wei Wu, Hong Fang, Qiong Du, Ning Li
Author Information
  1. Hui-Yao Huang: Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  2. Shu-Hang Wang: Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  3. Yu Tang: Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  4. Wei Sheng: Departmemt of Medical Affairs, ClinChoice Shanghai Branch, Shanghai, China.
  5. Chi-Jian Zuo: Department of Research and Development, Suzhou PureCodon Biomedical Technology Co., Ltd.
  6. Da-Wei Wu: Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  7. Hong Fang: Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  8. Qiong Du: Biometrics Department, ClinChoice Shanghai Branch,Shanghai, China.
  9. Ning Li: Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
PMID: 34254894 DOI: 10.1080/21645515.2021.1945901

Abstract

The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected billions of lives globally, and the world hopes to end this epidemic by effective vaccination. In this review, we depict the latest panorama of global COVID-19 vaccine research and development based on different technology platforms, and summarize key characteristics and available evidence on vaccines authorized for emergency use, in order to provide insights into improve coordination in the COVID-19 outbreak response for related stakeholders.

Keywords

COVID-19 Clinical trial lanscape vaccine

References

  1. Lancet. 2021 Jan 9;397(10269):99-111 [PMID: 33306989]
  2. ACS Cent Sci. 2020 Mar 25;6(3):315-331 [PMID: 32226821]
  3. JAMA. 2021 Jul 6;326(1):35-45 [PMID: 34037666]
  4. N Engl J Med. 2021 Apr 15;384(15):1412-1423 [PMID: 33626250]
  5. Lancet Infect Dis. 2021 May;21(5):637-646 [PMID: 33485468]
  6. Nat Mater. 2020 Aug;19(8):810-812 [PMID: 32704139]
  7. N Engl J Med. 2021 Feb 4;384(5):403-416 [PMID: 33378609]
  8. Lancet Infect Dis. 2021 Jan;21(1):39-51 [PMID: 33069281]
  9. Lancet. 2021 Feb 20;397(10275):671-681 [PMID: 33545094]
  10. N Engl J Med. 2020 Dec 31;383(27):2603-2615 [PMID: 33301246]
  11. Lancet. 2021 Apr 10;397(10282):1326-1327 [PMID: 33798497]

MeSH Term

COVID-19
COVID-19 Vaccines
Humans
SARS-CoV-2
Vaccination
Vaccines

Chemicals

COVID-19 Vaccines
Vaccines
Journal Article Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 10

Word Cloud

Created with Highcharts 10.0.0COVID-19vaccineglobaldevelopmentemergencesevereacuterespiratorysyndromecoronavirus-2SARS-CoV-2affectedbillionslivesgloballyworldhopesendepidemiceffectivevaccinationreviewdepictlatestpanoramaresearchbaseddifferenttechnologyplatformssummarizekeycharacteristicsavailableevidencevaccinesauthorizedemergencyuseorderprovideinsightsimprovecoordinationoutbreakresponserelatedstakeholdersLandscapeprogressClinicaltriallanscape

Similar Articles

Cited By (23)